Efficacy of The Ranitidine Bismuth Citrate And Chlaritromycin Combination For Ulcer Healing And
Helicobacter Pylori EradicationMurat Aladağ*, Melih Karıncaoğlu*, Bülent Kantarçeken*, Murat M.M. Harputluoğlu*, Mehmet Ateş*, Ayşe Sertkaya*, Bülent Yıldırım*, Fatih Hilmioğlu*.
Helicobacter pylori (Hp) infection is an infectious disease that can cause various gastrointestinal disorders such as
gastrit, peptic ulcus and MALTOMA. These disorders and related complications can be prevented by the
eradication of Hp. In this study we aimed to investigate the effectiveness of Ranitidine bismuth citrate and
clarithromycine combination which have been in use against this infection in our country for three years. 45
patient ( 32 male, 13 female), mean age 38 (20-60) who were diagnosed as having gastric or duodenal ulcus by the
oesophagogastroduodenoscopy (OGD) and the detection of Hp in their biopsies were included in the study.
Ranitidine bismuth citrate 2x400 mg for one month + Clarithromycin 2x500 mg were given to the patients for
one week. OGD was performed in patients on day 15 and day 45 and biopsies were taken again. Hp negatives in
repeated biopsies were considered as “eradication”. Eleven of the 45 patients were excluded in the study, since
they did not attend the control, their OGD and subsequent biopsies on day 15 could not be conducted. The
eradication rates of the cases on day 15 and 45 days were 85.2% (29/34) and 91.1% (31/34) respectively. The
ulcus healing rates were 88.2% (30/34), 94.1% (32/34) respectively. While there was no complain to cause the
withdrawal of therapy, the most common side-effects seen were tastelessness and mild abdominal pain.
As a result ıt was found that one week Ranitidine bismuth citrate therapy in the Hp eradication and ulcus healing
was efficacious and comparable with the other triple combination therapies.
Key Words: Helicobacter Pylori, Claritromycin, Ranitidine Bismuthcitrate, Ulcer Healing